Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITA-2: Efficacy and Safety of Follitropin Delta in Women 35-42 Undergoing IVF
NCT03738618Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in female infertility comparing Rekovelle with Placebo (2 arms). Primary endpoint: Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months. Started Oct 2018; status: completed.
02
Drugs
follitropin delta
03
Conditions
female infertility
Beyond the preview
Go deeper on NCT03738618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03738618.